AI Labs
Isomorphic Labs
30-Second Executive Brief
Executive Assessment
Isomorphic Labs functions as a regional institution within AI Labs, backed by 37% sourcing coverage, though its relative influence is cooling.
- Maintains 7 mapped relationships across the graph
- 37% sourcing coverage across sourced relationships
- Tracked as regional institution within the AI Labs category
Executive Snapshot
- Strategic Role
- Regional Institution
- Sourcing Coverage
- 37%
- Ecosystem Influence
- Moderate
- Strategic Momentum
- Decelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 7
- Technology Domains
- 4
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
An Alphabet-spun-out AI drug discovery company built on DeepMind's AlphaFold protein-structure technology, which raised a $2.1 billion Series B round in May 2026 led by Thrive Capital with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. Isomorphic Labs holds multi-drug R&D alliances with Eli Lilly, Novartis, and Johnson & Johnson, and is targeting its first human clinical trials by late 2026.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
3 sources
- BioSpace / PR Newswire — Isomorphic Labs raises $2.1B Series B to scale AI drug design enginenews
- pharmaphorum — Isomorphic Labs details use of Series B proceeds: clinical trials, international hiringnews
- Isomorphic Labs corporate site — Isomorphic Labs' pharma alliance portfolio spans Lilly, Novartis, and J&Jcompany
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Isomorphic Labs — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
Two credible sources report different Series B totals for the same round
22% confidenceIsomorphic Labs' own May 2026 announcement stated its Series B round totaled $2.1 billion, while July 2026 coverage described the same round as $1.2 billion, a discrepancy the later reporting attributed to possibly different tranches or reporting conventions.
This is InsightNodes' own interpretive read: Isomorphic Labs' own May 2026 announcement puts its Series B at $2.1 billion, while July 2026 coverage cites $1.2 billion, possibly reflecting different tranches or reporting conventions of the same round rather than a correction. Until the discrepancy is reconciled, it's worth treating the larger, company-disclosed figure as the more authoritative number while flagging the gap.
pharmaphorum · Aug 14, 2026
Isomorphic Labs's Timeline
A sourced, dated history of Isomorphic Labs's key moments — founding to present.
Jan 2021 · Spun out of Alphabet/DeepMind
Isomorphic Labs was spun out of Alphabet, building on DeepMind's AlphaFold protein-structure prediction technology to pursue AI-driven drug discovery.
May 2026 · $2.1B Series B round
Isomorphic Labs raised a $2.1 billion Series B round led by Thrive Capital, with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, to scale its IsoDDE AI drug design engine and expand its therapeutic pipeline toward the clinic.